PortfoliosLab logo
PortfoliosLab logo
Tools
Performance Analysis
Portfolio Analysis
Factor Model
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
CLOV vs. NKE
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Correlation

The correlation between CLOV and NKE is 0.30, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.


-0.50.00.51.00.3

Performance

CLOV vs. NKE - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Clover Health Investments, Corp. (CLOV) and NIKE, Inc. (NKE). The values are adjusted to include any dividend payments, if applicable.

0.00%50.00%100.00%150.00%200.00%SeptemberOctoberNovemberDecember2025
162.92%
4.91%
CLOV
NKE

Key characteristics

Sharpe Ratio

CLOV:

4.08

NKE:

-0.77

Sortino Ratio

CLOV:

4.19

NKE:

-0.86

Omega Ratio

CLOV:

1.50

NKE:

0.86

Calmar Ratio

CLOV:

3.52

NKE:

-0.43

Martin Ratio

CLOV:

19.18

NKE:

-1.15

Ulcer Index

CLOV:

17.84%

NKE:

21.75%

Daily Std Dev

CLOV:

83.92%

NKE:

32.19%

Max Drawdown

CLOV:

-97.19%

NKE:

-64.43%

Current Drawdown

CLOV:

-80.18%

NKE:

-54.80%

Fundamentals

Market Cap

CLOV:

$2.20B

NKE:

$115.86B

EPS

CLOV:

-$0.19

NKE:

$3.18

Total Revenue (TTM)

CLOV:

$1.03B

NKE:

$48.98B

Gross Profit (TTM)

CLOV:

$465.18M

NKE:

$21.84B

EBITDA (TTM)

CLOV:

-$22.84M

NKE:

$5.91B

Returns By Period

In the year-to-date period, CLOV achieves a 39.37% return, which is significantly higher than NKE's 1.63% return.


CLOV

YTD

39.37%

1M

39.37%

6M

162.87%

1Y

339.00%

5Y*

N/A

10Y*

N/A

NKE

YTD

1.63%

1M

1.63%

6M

4.91%

1Y

-23.13%

5Y*

-3.30%

10Y*

6.35%

*Annualized

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Risk-Adjusted Performance

CLOV vs. NKE — Risk-Adjusted Performance Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

CLOV
The Risk-Adjusted Performance Rank of CLOV is 9797
Overall Rank
The Sharpe Ratio Rank of CLOV is 9999
Sharpe Ratio Rank
The Sortino Ratio Rank of CLOV is 9797
Sortino Ratio Rank
The Omega Ratio Rank of CLOV is 9595
Omega Ratio Rank
The Calmar Ratio Rank of CLOV is 9696
Calmar Ratio Rank
The Martin Ratio Rank of CLOV is 9797
Martin Ratio Rank

NKE
The Risk-Adjusted Performance Rank of NKE is 1414
Overall Rank
The Sharpe Ratio Rank of NKE is 99
Sharpe Ratio Rank
The Sortino Ratio Rank of NKE is 1313
Sortino Ratio Rank
The Omega Ratio Rank of NKE is 1010
Omega Ratio Rank
The Calmar Ratio Rank of NKE is 2121
Calmar Ratio Rank
The Martin Ratio Rank of NKE is 1717
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

CLOV vs. NKE - Risk-Adjusted Performance Comparison

This table presents a comparison of risk-adjusted performance metrics for Clover Health Investments, Corp. (CLOV) and NIKE, Inc. (NKE). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


Sharpe ratio
The chart of Sharpe ratio for CLOV, currently valued at 4.08, compared to the broader market-2.000.002.004.08-0.77
The chart of Sortino ratio for CLOV, currently valued at 4.19, compared to the broader market-4.00-2.000.002.004.004.19-0.86
The chart of Omega ratio for CLOV, currently valued at 1.50, compared to the broader market0.501.001.502.001.500.86
The chart of Calmar ratio for CLOV, currently valued at 3.52, compared to the broader market0.002.004.006.003.52-0.43
The chart of Martin ratio for CLOV, currently valued at 19.18, compared to the broader market-5.000.005.0010.0015.0020.0025.0019.18-1.15
CLOV
NKE

The current CLOV Sharpe Ratio is 4.08, which is higher than the NKE Sharpe Ratio of -0.77. The chart below compares the historical Sharpe Ratios of CLOV and NKE, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.


Rolling 12-month Sharpe Ratio-1.000.001.002.003.004.005.00SeptemberOctoberNovemberDecember2025
4.08
-0.77
CLOV
NKE

Dividends

CLOV vs. NKE - Dividend Comparison

CLOV has not paid dividends to shareholders, while NKE's dividend yield for the trailing twelve months is around 1.96%.


TTM20242023202220212020201920182017201620152014
CLOV
Clover Health Investments, Corp.
0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%
NKE
NIKE, Inc.
1.96%2.00%1.28%1.07%0.68%0.71%0.89%1.11%1.18%1.30%0.93%1.04%

Drawdowns

CLOV vs. NKE - Drawdown Comparison

The maximum CLOV drawdown since its inception was -97.19%, which is greater than NKE's maximum drawdown of -64.43%. Use the drawdown chart below to compare losses from any high point for CLOV and NKE. For additional features, visit the drawdowns tool.


-90.00%-80.00%-70.00%-60.00%-50.00%SeptemberOctoberNovemberDecember2025
-80.18%
-54.80%
CLOV
NKE

Volatility

CLOV vs. NKE - Volatility Comparison

Clover Health Investments, Corp. (CLOV) has a higher volatility of 14.49% compared to NIKE, Inc. (NKE) at 7.69%. This indicates that CLOV's price experiences larger fluctuations and is considered to be riskier than NKE based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


0.00%10.00%20.00%30.00%40.00%SeptemberOctoberNovemberDecember2025
14.49%
7.69%
CLOV
NKE

Financials

CLOV vs. NKE - Financials Comparison

This section allows you to compare key financial metrics between Clover Health Investments, Corp. and NIKE, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


Values in USD except per share items
PortfoliosLab logo
Performance Analysis
Portfolio AnalysisPortfolio PerformanceStock ComparisonSharpe RatioMartin RatioTreynor RatioSortino RatioOmega RatioCalmar RatioSummers Ratio
Community
Discussions


Disclaimer

The information contained herein does not constitute investment advice and made available for educational purposes only. Prices and returns on equities are listed without consideration of fees, commissions, taxes, penalties, or interest payable due to purchasing, holding, or selling.

Copyright © 2025 PortfoliosLab